{
    "name": "COVID-19 vaccine, viral vector-Janssen",
    "comment": "Investigational",
    "other_names": [
        "Ad26.COV2.S (Johnson & Johnson)"
    ],
    "classes": [
        "Vaccines",
        "Inactivated",
        "Viral"
    ],
    "source": "https://reference.medscape.com/drug/ad26cov2s-johnson-johnson-covid-19-vaccine-viral-vector-janssen-4000143",
    "pregnancy": {
        "common": [
            "Data are insufficient to inform of vaccine-associated risks in pregnancy",
            "Women vaccinated with Janssen COVID-19 vaccine are encouraged to enroll in the ",
            "A smartphone app, ",
            null
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are not available to assess effects on breastfed infants or on milk production/excretion"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known history of severe allergic reaction (eg, anaphylaxis) to any component in vaccine ",
                "History of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine or any other adenovirus vectored COVID-19 vaccine (eg, AstraZeneca COVID-19 vaccine which is not authorized or approved in the United States) "
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Vaccine may not protect all vaccine recipients",
                "Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have diminished immune response to the vaccine ",
                "Post authorization reports suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination ",
                "Post authorization reports also suggest increased risk of myocarditis and pericarditis, particularly within the first 7 days after vaccination ",
                "Syncope (fainting) may occur; procedures should be in place to avoid injury from fainting ",
                "Post authorization reports suggest an increased risk of immune thrombocytopenia (ITP) during the 42 days following vaccination; individuals with history of ITP should discuss the potential need for platelet monitoring following vaccination with their healthcare clinician "
            ],
            "specific": [
                {
                    "type": "Allergic reactions",
                    "description": [
                        "Appropriate medical treatment used to manage immediate allergic reactions must be immediately available following vaccination",
                        "Individuals with histories of severe allergic reaction to vaccines should consult their doctors about the COVID-19 vaccine",
                        "Monitor vaccine recipients for immediate adverse reactions according to the ",
                        "Centers for Disease Control and Prevention guidelines"
                    ]
                },
                {
                    "type": "Thrombosis with thrombocytopenia syndrome (TTS) ",
                    "description": [
                        "Extremely rare cases reported of thrombosis involving the cerebral venous sinuses and other sites (including but not limited to the large blood vessels of the abdomen and the veins of the lower extremities) combined with thrombocytopenia",
                        "Onset of symptoms ~1-2 weeks after vaccination ",
                        "Reporting rate of thrombosis and thrombocytopenia has been highest in females aged 18-49 years; some have been fatal ",
                        "Healthcare professionals should be alert to the signs and symptoms of thrombosis with thrombocytopenia in individuals who received the Ad26.COV2-2 vaccine",
                        "VAERS reports",
                        "Through March 18, 2022: ",
                        "Analysis of TTS",
                        " cases following Janssen COVID-19 vaccine reported to VAERS, 60 confirmed cases have been identified, including 9 fatal cases ",
                        "The reporting rate of TTS is 3.23 per million doses of vaccine administered and the reporting rate of TTS deaths is 0.48 per million doses of vaccine administered ",
                        "TTS definition",
                        "Thrombosis in an unusual location for a thrombus (ie, cerebral vein, visceral artery or vein, extremity artery, central artery or vein) and new-onset thrombocytopenia (ie, platelet count <150,000/μL) occurring any time after vaccination, OR",
                        "New-onset thrombocytopenia, thrombosis in an extremity vein or pulmonary artery in absence of thrombosis at an unusual location, and a positive anti-PF4 antibody ELISA test or functional heparin-induced thrombocytopenia (HIT) platelet test occurring any time after vaccination",
                        "Clinical course",
                        "The clinical course shares features with autoimmune HIT  ",
                        "Use of heparin may be harmful in individuals with suspected thrombosis with thrombocytopenia following vaccination; alternant treatments may be needed  ",
                        "Diagnosis must include the following 4 criteria: 1) Ad26.COV2-2 vaccine 4-30 days previously; 2) thrombosis (often cerebral or abdominal); 3) thrombocytopenia; 4) positive PF4 HIT ELISA",
                        "NOTE: If patient presents with thrombosis and a normal platelet count post-vaccination, they might be in an early stage of VITT; continued assessment for development of thrombocytopenia/VITT required",
                        "Cases reported in males and females, in wide age range (≥18 yr), with the highest reporting rate (~1 case/100,000 doses administered) in females aged 30-49 yr",
                        "Overall, ~15% of TTS cases have been fatal ",
                        "Hematology consultation",
                        "Consultation with hematology specialists is strongly recommended ",
                        "American Society of Hematology",
                        " has published considerations relevant to the diagnosis and treatment of thrombosis with thrombocytopenia following vaccination",
                        "Urgent medical evaluation for vaccine-induced immune thrombotic thrombocytopenia (VITT) indicated if any of the following develops: severe headache, visual changes, abdominal pain, nausea/vomiting, backache, shortness of breath, leg pain/swelling, or petechiae/easy bruising "
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Data are not available to assess concomitant administration with other vaccines"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site pain",
            "percent": "58.6"
        },
        {
            "name": "Headache",
            "percent": "44.4"
        },
        {
            "name": "Fatigue",
            "percent": "43.8"
        },
        {
            "name": "Myalgia",
            "percent": "39.1"
        },
        {
            "name": "Use of antipyretic or pain medication",
            "percent": "26.4"
        },
        {
            "name": "Nausea",
            "percent": "15.5"
        },
        {
            "name": "Fever",
            "percent": "12.8"
        },
        {
            "name": "Injection site pain",
            "percent": "33.3"
        },
        {
            "name": "Headache",
            "percent": "30.4"
        },
        {
            "name": "Fatigue",
            "percent": "29.7"
        },
        {
            "name": "Myalgia",
            "percent": "24"
        },
        {
            "name": "Nausea",
            "percent": "12.3"
        },
        {
            "name": "Injection site erythema",
            "percent": "9"
        },
        {
            "name": "Injection site swelling",
            "percent": "7"
        },
        {
            "name": "Myalgia",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "1.4"
        },
        {
            "name": "Fatigue",
            "percent": "3"
        },
        {
            "name": "Grade",
            "percent": "1.2"
        },
        {
            "name": "Use of antipyretic or pain medication",
            "percent": "9.8"
        },
        {
            "name": "Injection site erythema",
            "percent": "4.6"
        },
        {
            "name": "Fever",
            "percent": "3.1"
        },
        {
            "name": "Injection site swelling",
            "percent": "2.7"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "0.9"
        },
        {
            "name": "Injection site pain",
            "percent": "0.4"
        },
        {
            "name": "Injection site erythema",
            "percent": "0.3"
        },
        {
            "name": "Fever",
            "percent": "0.3"
        },
        {
            "name": "Injection site swelling",
            "percent": "0.2"
        },
        {
            "name": "Nausea",
            "percent": "0.1"
        },
        {
            "name": "Headache",
            "percent": "0.9"
        },
        {
            "name": "Injection site pain",
            "percent": "0.4"
        },
        {
            "name": "Injection site erythema",
            "percent": "0.3"
        },
        {
            "name": "Fever",
            "percent": "0.3"
        },
        {
            "name": "Injection site swelling",
            "percent": "0.2"
        },
        {
            "name": "Nausea",
            "percent": "0.1"
        },
        {
            "name": "Grade",
            "percent": "3"
        },
        {
            "name": "Fatigue",
            "percent": "0.8"
        },
        {
            "name": "Headache",
            "percent": "0.4"
        },
        {
            "name": "Injection site pain",
            "percent": "0.2"
        },
        {
            "name": "Injection site swelling",
            "percent": "0.2"
        },
        {
            "name": "Myalgia",
            "percent": "0.2"
        },
        {
            "name": "Injection site erythema",
            "percent": "0.1"
        },
        {
            "name": "Fever",
            "percent": "0.1"
        },
        {
            "name": "Fatigue",
            "percent": "0.8"
        },
        {
            "name": "Headache",
            "percent": "0.4"
        },
        {
            "name": "Injection site pain",
            "percent": "0.2"
        },
        {
            "name": "Injection site swelling",
            "percent": "0.2"
        },
        {
            "name": "Myalgia",
            "percent": "0.2"
        },
        {
            "name": "Injection site erythema",
            "percent": "0.1"
        },
        {
            "name": "Fever",
            "percent": "0.1"
        }
    ]
}